Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | INBX |
---|---|---|
09:32 ET | 1440 | 14.8101 |
09:57 ET | 100 | 14.89 |
10:03 ET | 100 | 14.9 |
11:02 ET | 100 | 15.01 |
11:11 ET | 1000 | 15.0109 |
11:42 ET | 100 | 14.91 |
01:03 ET | 614 | 14.985 |
01:17 ET | 400 | 14.93 |
01:30 ET | 400 | 14.91 |
01:35 ET | 300 | 14.82 |
01:44 ET | 300 | 14.815 |
01:53 ET | 200 | 14.76 |
02:00 ET | 100 | 14.79 |
02:09 ET | 100 | 14.78 |
02:26 ET | 100 | 14.79 |
02:29 ET | 200 | 14.75 |
02:44 ET | 652 | 14.78 |
02:45 ET | 200 | 14.78 |
02:58 ET | 300 | 14.82 |
03:02 ET | 100 | 14.78 |
03:14 ET | 100 | 14.7625 |
03:23 ET | 145 | 14.78 |
03:27 ET | 185 | 14.7685 |
03:32 ET | 636 | 14.815 |
03:34 ET | 1202 | 14.8 |
03:36 ET | 100 | 14.79 |
03:38 ET | 1885 | 14.77 |
03:39 ET | 600 | 14.77 |
03:41 ET | 2000 | 14.745 |
03:43 ET | 100 | 14.76 |
03:45 ET | 700 | 14.77 |
03:48 ET | 1300 | 14.76 |
03:50 ET | 700 | 14.79 |
03:52 ET | 706 | 14.76 |
03:54 ET | 3014 | 14.72 |
03:56 ET | 2000 | 14.74 |
03:57 ET | 2642 | 14.74 |
03:59 ET | 12486 | 14.76 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Inhibrx Biosciences Inc | 215.4M | 0.1x | --- |
Candel Therapeutics Inc | 215.3M | -3.9x | --- |
XBiotech Inc | 214.8M | -6.5x | --- |
Immutep Ltd | 310.4M | -8.5x | --- |
Acrivon Therapeutics Inc | 213.4M | -2.5x | --- |
Trevi Therapeutics Inc | 219.2M | -7.8x | --- |
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. The Company’s clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106. INBRX-109 is a tetravalent agonist of death receptor 5 (DR5) that is designed with its proprietary single domain antibody, or sdAb, platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis. INBRX-106 is a hexavalent OX40 agonist, being investigated as a single agent and in combination with Keytruda, a PD-1 blocking checkpoint inhibitor, in patients with locally advanced or metastatic solid tumors. INBRX-106 is a precisely engineered hexavalent sdAb-based therapeutic candidate targeting OX40, designed to be an optimized agonist of this co-stimulatory receptor.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $215.4M |
---|---|
Revenue (TTM) | $1.9M |
Shares Outstanding | 14.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $121.21 |
Book Value | $0.92 |
P/E Ratio | 0.1x |
Price/Sales (TTM) | 116.2 |
Price/Cash Flow (TTM) | 0.1x |
Operating Margin | 89,188.29% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.